204 related articles for article (PubMed ID: 18088497)
21. Dickkopf-1: a suitable target for the management of myeloma bone disease.
Gavriatopoulou M; Dimopoulos MA; Christoulas D; Migkou M; Iakovaki M; Gkotzamanidou M; Terpos E
Expert Opin Ther Targets; 2009 Jul; 13(7):839-48. PubMed ID: 19530987
[TBL] [Abstract][Full Text] [Related]
22. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic approaches to myeloma bone disease: an evolving story.
Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
[TBL] [Abstract][Full Text] [Related]
24. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
25. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
[TBL] [Abstract][Full Text] [Related]
26. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
27. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibitors and bone disease.
Qiang YW; Heuck CJ; Shaughnessy JD; Barlogie B; Epstein J
Semin Hematol; 2012 Jul; 49(3):243-8. PubMed ID: 22726547
[TBL] [Abstract][Full Text] [Related]
29. Why do myeloma patients have bone disease? A historical perspective.
Børset M; Sundan A; Waage A; Standal T
Blood Rev; 2020 May; 41():100646. PubMed ID: 31810754
[TBL] [Abstract][Full Text] [Related]
30. Treatment strategies for bone disease.
Roodman GD
Bone Marrow Transplant; 2007 Dec; 40(12):1139-46. PubMed ID: 17680018
[TBL] [Abstract][Full Text] [Related]
31. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
32. The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease.
Brunetti G; Colucci S; Rizzi R; Mori G; Colaianni G; Oranger A; Zallone A; Liso V; Grano M
Ann N Y Acad Sci; 2006 Apr; 1068():334-40. PubMed ID: 16831934
[TBL] [Abstract][Full Text] [Related]
33. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
Heider U; Hofbauer LC; Zavrski I; Kaiser M; Jakob C; Sezer O
Biochem Biophys Res Commun; 2005 Dec; 338(2):687-93. PubMed ID: 16216218
[TBL] [Abstract][Full Text] [Related]
34. Myeloma bone disease: pathogenetic mechanisms and clinical assessment.
Silvestris F; Lombardi L; De Matteo M; Bruno A; Dammacco F
Leuk Res; 2007 Feb; 31(2):129-38. PubMed ID: 16764925
[TBL] [Abstract][Full Text] [Related]
35. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
36. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D; Maalouf NM; Sakhaee K
J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
[TBL] [Abstract][Full Text] [Related]
37. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
38. The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival.
Ochi H; Hara Y; Tagawa M; Shinomiya K; Asou Y
J Orthop Res; 2010 May; 28(5):657-63. PubMed ID: 19890995
[TBL] [Abstract][Full Text] [Related]
39. Myeloma bone disease: Progress in pathogenesis.
Xi H; An R; Li L; Wang G; Tao Y; Gao L
Prog Biophys Mol Biol; 2016 Nov; 122(2):149-155. PubMed ID: 27496181
[TBL] [Abstract][Full Text] [Related]
40. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
